Coherus Oncology
CHRS
109 hedge funds and large institutions have $793M invested in Coherus Oncology in 2017 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 25 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 25
25% more call options, than puts
Call options by funds: $6.08M | Put options by funds: $4.85M
4.78% more ownership
Funds ownership: 68.52% → 73.3% (+4.8%)
6% less capital invested
Capital invested by funds: $842M → $793M (-$49M)
11% less funds holding
Funds holding: 122 → 109 (-13)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$69.9M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$36.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.6M |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$19.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.9M |
| 2 |
Two Sigma Investments
New York
|
-$3.25M |
| 3 |
Morgan Stanley
New York
|
-$2.12M |
| 4 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$2.11M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$1.69M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
126
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
| – | -$423K | -15,017 | Closed |
|
127
Walleye Trading
New York
| – | -$357K | -14,500 | Closed |
|
|
AL
128
Airain Ltd
St. Peter Port,
Guernsey
| – | -$376K | -13,371 | Closed |
|
|
HLA
129
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$265K | -9,399 | Closed |
|
130
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$221K | -8,984 | Closed |
|
|
BC
131
Birchview Capital
Burlington,
Vermont
| – | -$211K | -7,500 | Closed |
|
|
AIM
132
Acrospire Investment Management
Chicago,
Illinois
| – | -$32K | -1,131 | Closed |
|
133
Creative Planning
Overland Park,
Kansas
| – | -$31K | -1,097 | Closed |
|
|
QT
134
Quantbot Technologies
New York
| – | -$14K | -521 | Closed |
|
|
PHK
135
Point72 Hong Kong
Hong Kong
| – | -$14K | -485 | Closed |
|
CHRS Hedge Fund Activity: Q1 2017 in Review
109 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2017, worth a combined $793M — down 5.8% from $842M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CHRS and 21 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 50 added.
The largest buyer was BlackRock, adding an estimated $69.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $16.9M sold.
- 109 institutional investors held Coherus Oncology (CHRS) as of Q1 2017, down from 122 in Q4 2016.
- Funds reported $793M of Coherus Oncology stock for Q1 2017, down 5.8% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q1 2017 and 25 closed out, a net change of -4 holders.
- The largest Coherus Oncology buyer in Q1 2017 was BlackRock, an estimated $69.9M added.
- The largest Coherus Oncology seller in Q1 2017 was Point72 Asset Management, an estimated $16.9M sold.
Based on aggregated 13F filings for Q1 2017.